The combination of the third‐generation BCR–ABL1 inhibitor olverembatinib with the Bcl‐2 inhibitor venetoclax has shown high efficacy in relapsed Ph+ acute lymphoblastic leukemia (ALL) patients. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.